The progression of HCC is driven by the dysregulation of key oncogenic pathways, such as the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway, which is known to promote cell proliferation, inhibit apoptosis, and enhance cancer cell survival [12]. Here, MTOR is linked to hepatocellular carcinoma.